在尼日利亚卡诺的一些医院就诊的病人尿路病原体中β -内酰胺酶的产生

Hamza Sule, Abdulhadi Kumurya
巴耶罗大学联合健康科学学院医学检验科学系

摘要

细菌耐受抗生素治疗的能力通常与耐药性有关。某些细菌有能力产生一些酶，比如β -内酰胺酶，它能对青霉素类和
头孢菌素类等某些抗生素产生耐药性。这项研究的重点是尿路病原体中这些酶的生产者。共筛选分离株 114 株，其中 71771
株(62.3%)酶阳性。大肠埃希菌阳性率最高 40 例(56.3%)。其次为克雷伯菌、金黄色葡萄球菌、腐生葡萄球菌、奇异变形杆菌、
铜绿假单胞菌，分别为 15 例(21.1%)、7 例(10.0%)、5 例(7.0%)、3 例(4.2%)、1 例(1.4%)。同样，研究人员发现，来自女性的
菌株比来自男性的菌株产生更多的酶。这表明，从雌性样本中分离出来的每个物种中至少有一种分离物产生酶，而在雄性样
本中，有些物种甚至不产生任何酶。酶的年龄分布表明，21-30 岁和 31-40 岁年龄组的所有分离菌都以不同的频率产生酶。只
有铜绿假单胞菌能在这些年龄组之外产生酶。女性来源的菌株在所有物种中产生的酶都高于男性来源的菌株，其比例为;分别
为大肠杆菌 26:14、11:4、5:2、3:2、2:1、1:0、克雷伯氏菌种、金黄色葡萄球菌、腐生葡萄球菌、奇异变形杆菌、铜绿假单胞
菌。

关键词

尿路感染；尿路病原体；β-内酰胺酶；卡诺

参考

[1] Abigail, A. Dixie; W. (2005). Bacterial Pathogenesis: A

Molecular approach, Washington DC ASM Press,. 2005. [2] Alabi, O. S., Onyenwe, N. E. Satoye, K. A. and Adeleke, O. E. (2014). Prevalence of extended-spectrum β-lactamase producing isolates from asymptomatic bacteriuria among

students in a tertiary institution in Ibadan, Nigeria. Nature and

Science 12 (4): 113. [3] Al-Issa, M. (2009). Urinary tract infection among

pregnant women in north Jordan. Middle East J Fam Med., 7: 10-4.[4] Ben–Ami, R., Rodriguez–Bafio, J., Calbo E. S. And

Arslan, H. A. (2009). Multinational survey of risk factors for

infection with extended spectrum beta lactamasesmproducing

Enterobacteriaceae in non hospitalized patients. 5 (1): 49–51. [5] Bush, K., Jacoby, G. A. and Medeiros, A. A. (1995). A

Functional Classification Scheme for β- lactamases and its Correlation with Molecular Structure. Antimicrob. Agents Chemother. 39: 1211-33. [6] Chaliha, C. Stanton, S. L., (2002). Urological problems

in pregnancy. BJU Int., 89 (5): 469-76. To remove

[7] Chander and Shrestha, (2013). Prevalence of extended

spectrum beta lactamase producing Escherichia coli and

Klebsiella pneumoniae urinary isolates in a tertiary care hospital

in Kathmandu, Nepal. BMC Research Notes 6: 487. [8] Cheesebrough, M. (2000). Distric Laboratory Practice

in Tropical Countries Low Price ed. Chambridge University

Press. Pp. 434. [9] Cox, C. E. (1988). Nosocomial urinary tract infections. Urol, 32 (3): 210–215. [10] Datta, N. and Kontomichalou, P. (1965)."Penicillinase

synthesis controlled by infectious R factors in Enterobacteriaceae." Nature 208: 239-41. [11] Foxman, B., Barlow, R., D’Arcy, H., Gillespie, B., and

Sobel, J. D. (2000). Urinary tract infection: Self-reported

incidence and associated costs. Ann Epidemiol; 10 (8): 509-15. [12] Gaurav, Dalela (2012). PREV. of Extended Spectrum

BetaLactamase (ESBL) Producers among Gram Negative Bacilli from Various Clinical Isolates in a Tertiary Care Hospital at Jhalawar, Rajasthan, India. Journal of Clinical and Diagnostic Research. 6 (2): 182-187. [13] Gonzalez, C. M., and Schaeffer, A. J. (1999). Treatment of urinary tract infection: what’s old, what’s new, and what works. World J Urol.; 17 (6): 372–382. [14] Kapur, A., Ahmed, M. S., and John, S. (2015). Prevalence of Extended-Spectrum Beta-Lactamase-Producing

Pathogens From Urinary Tract Infected Samples and Their Sensitivity Pattern Against Withania somnifera. Int J Infect. 2

(1): e22664. [15] Livermore, D. M. and Woodford, N. (2004). Laboratory detection and reporting of bacteria with extended

spectrum betalactamases. Antibiotic resistance monitoring and

reference laboratory, specialist and reference. Microbiology

division, Health Protection Agency -Colindale, London. [16] Maina, D., Makau, P., Nyerere, A. and Revathi, G. (2013). Antimicrobial resistance patterns in extended-spectrum

β-lactamase producing Escherichia coli and Klebsiella pneumoniae isolates in a private tertiary hospital, Kenya. Microbiology Discovery, 1 (5): 1-4. http://dx.doi.org/10.7243/2052-6180-1-5. [17] Mansour, A. Manijeh, M. and Zohreh, P. (2009). Study

of bacteria isolated from urinary tract infections and

determination of their susceptibility to antibiotics. Jundishapur J

Microbiol; 2 (3): 118–23. [18] Mackey, McCartney, (1996). Tropical Medical

Micrbiology 14th ed. Churchill Livingstone. London. Pp. 978. [19] Rai, G. Upretin, H., Rai, S., Saha, K. and Shrestha, R. (2008). Nepal Med Coll J. 10, 86. [20] Romero, L., López, L., Rodríguez-Baño, J., Ramón, Hernández, J., Martínez-Martínez, L., and Pascual, A. (2005). Long-term study of the frequency of Escherichia coli and

Klebsiella pneumoniae isolates producing extended-spectrum

beta-lactamases. Clin Microbiol Infect.; 11 (8): 625-31. [21] Rupp, M. E., and Fey, P. D. (2003). Extended

spectrum betalactamase (ESBL)-producing Enterobacteriaceae: Considerations for diagnosis, prevention and drug treatment. Drugs; 63 (4): 353-65. [22] Samaha-Kfoury, J. N., Araj, G. F. (2003). Recent

developments in β-lactamases and extended spectrum

β-lactamases. BMJ; 327: 1209-13. [23] Senkas-Dzidic, J., and Suskovic., B., (2008). Kos, Food Technolo. Biotechnolo., 46, 11. [24] Thapa, R., Pramila, L., Megha, Raj, B., and Ganesh, P. A. (2015). Prevalence of extended spectrum beta lactamase producing uropathogens in pregnant women. Asian J Pharm

Clin Res, 8 (1), 2015, 207-210. [25] Ullah, F., Malik, S. A, Ahmed J. (2009): Antibiotic

susceptibility pattern and ESBL prevalence in nosocomial

Escherichia coli from urinary tract infections in Pakistan. Afr J

Biotechnol, 8 (16): 3921–3926.